Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01688050 · ClinicalTrials.gov registry record · NA
TRANSFIX Zenith® Transection Clinical Study
A NA study, sponsored by Cook Research Incorporated.
- Completed
- Registry status
- NA
- Development phase
- 50
- Enrollment target
NCT01688050: Completed NA study, sponsored by Cook Research Incorporated.
NCT01688050 is a NA study that has completed, run by Cook Research Incorporated. The registered enrollment target is 50 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01688050, a NA study, has completed, sponsored by Cook Research Incorporated.
- COMPLETED
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
Study Summary
The TRANSFIX study is a clinical trial approved by US FDA to study the safety and effectiveness of the Zenith® TX2® Low Profile Endovascular Graft for treatment of Blunt Thoracic Aortic Injury.
Interventions
- DEVICE Zenith® TX2® Low Profile Endovascular Graft
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2013-01-23 |
| Est. Completion | 2019-07-29 |
| Phase | NA |
What the finished NCT01688050 record still lists
NCT01688050 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 1 intervention - of which Zenith® TX2® Low Profile Endovascular Graft is the first listed.
NCT01688050 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01688050 about?
NCT01688050 is a clinical study titled "TRANSFIX Zenith® Transection Clinical Study". The TRANSFIX study is a clinical trial approved by US FDA to study the safety and effectiveness of the Zenith® TX2® Low Profile Endovascular Graft for treatment of Blunt Thoracic Aortic Injury.
What is the current status of trial NCT01688050?
This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2013-01-23. Estimated completion is 2019-07-29.
What interventions are being tested in trial NCT01688050?
The interventions under investigation include: Zenith® TX2® Low Profile Endovascular Graft (DEVICE).
Who is sponsoring clinical trial NCT01688050?
This trial is sponsored by Cook Research Incorporated, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01688050's enrollment target sits among peer trials
50 1279th of 2000 higher than 622 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI